KRAS-mutant lung cancers in the era of targeted therapy. Adv Exp Med Biol 2016;893:155-78.Naidoo, J.; Drilon, A. Kras-mutant lung cancers in the era of targeted therapy. Adv. Exp. Med. Biol. 2016, 893, 155-178. [PubMed]
[1] FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy. Retrieved May 28, 2021, from https://www.prnewswire.com/news-releases/fda-approves-first-targeted-therapy-for-lung-cancer-mutation-previously-considered-resistant-to-drug-therapy-301301797...
11. Akhave, N.S., Biter, A.B., and Hong, D.S. (2021). Mechanisms of Resistance to KRASG12C-Targeted Therapy. Cancer Discov. 11, 1345–1352. 12. Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z...
Sotorasib与程序性死亡[蛋白]配体-1(programmed death ligand-1,PD-L1)抑制剂联合治疗KRASG12C突变的非小细胞肺癌(non-small cell lung cancer,NSCLC)的CodeBreak100/101研究结果显示,联用阿替利珠单抗后的安全性要明显高于联用帕博利珠单抗,同时sotora...
[1]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug [2]. Cox A D, Der CJ. Ras history: The saga continues[J]. Small GTPases, 2010, 1(1): 2-27.[3]. Santos E,Martin-Zanca D, Reddy E...
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012;44(8):852–60. Article CAS PubMed PubMed Central Google Scholar Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The KRAS(G12C) inhibitor MRTX849 ...
Pilotto S, Molina-Vila MA, Karachaliou N, et al. Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Transl Lung Cancer Res, 2015, 4(6): 721-727. doi: 10.3978/j.issn.2218...
Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substan
想要获取本文所编译的参考文献原文,可以后台私信20180811获取。 参考文献: Wu CK,et al., Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations. J Thorac Oncol. 2018 Jun;13(6):e103-e105....
Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substan